Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Launxp Biomedical CoROCO:6876 +1.67%17 Gross Margin % is 35.97% as of Jun. 2026, which is 48% below its 10-year median of 69.62. GuruFocus rates ROCO:6876 with a GF Score™ of 17/100. The stock has 4 warning signs investors should review. Among 738 Biotechnology companies, Launxp Biomedical Co ranks worse than 72.9% on this metric.
Launxp Biomedical Co (ROCO:6876) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Launxp Biomedical Co had a gross margin of 35.97% for the quarter that ended in Jun. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Launxp Biomedical Co Gross Margin % Related Terms
Launxp Biomedical Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for Launxp Biomedical Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6876 vs VRTX, REGN, MRNA: Gross Margin % Comparison
For the Biotechnology subindustry, Launxp Biomedical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Launxp Biomedical Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Launxp Biomedical Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Launxp Biomedical Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Launxp Biomedical Co (ROCO:6876) has a Gross Margin % of 35.97% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Launxp Biomedical Co and its competitors. This is 48% below median its historical median of 69.62. Over the past decade, Launxp Biomedical Co's Gross Margin % has ranged from 35.97 to 91.99. According to the industry distribution chart, Launxp Biomedical Co ranks #538 out of 738 companies in the Biotechnology industry, placing it in the top 72.9%.
Is Launxp Biomedical Co's Gross Margin % too high?
Launxp Biomedical Co's current Gross Margin % of 35.97% is 48% below median its 10-year median of 69.62. Over the past 10 years, this metric has ranged from a low of 35.97 to a high of 91.99. The Biotechnology industry median Gross Margin % is 60.94. Launxp Biomedical Co's value of 35.97% is 41% below this industry median. Based on the distribution chart, Launxp Biomedical Co ranks #538 out of 738 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Launxp Biomedical Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Launxp Biomedical Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Launxp Biomedical Co ranks #538 out of 738 companies for Gross Margin %. This places Launxp Biomedical Co in the lower half of its industry. The industry median Gross Margin % is 60.94. Launxp Biomedical Co's value of 35.97% is 41% below this benchmark. Historically, Launxp Biomedical Co's own Gross Margin % has ranged from 35.97 to 91.99 over the past decade. While the company's 10-year median is 69.62 vs. the industry median of 60.94, Launxp Biomedical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Launxp Biomedical Co's current Gross Margin % of 35.97% is 41% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Launxp Biomedical Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Launxp Biomedical Co's current Gross Margin % is 35.97%, which is 48% below median its own 10-year median of 69.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Launxp Biomedical Co stock overvalued right now?
Launxp Biomedical Co (ROCO:6876) has a current Gross Margin % of 35.97%. The current Gross Margin % is 35.97%, which is 48% below median its 10-year median of 69.62 and 41% below the Biotechnology industry median of 60.94. Launxp Biomedical Co's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Launxp Biomedical Co (ROCO:6876), the current Gross Margin % is 35.97% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Launxp Biomedical Co Ltd is a company that researches, designs and develops Cancer drug rapid screening platform and Early development evaluation and technology licensing of generic drugs for cancer treatment. The company mainly focuses on the screening of development drugs, formulation of development strategies, project management, planning and execution of regulations and clinical trials, etc.
17GF Score
Get the complete analysis for ROCO:6876
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6876 has been successfully added to your 
